Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase

ELIGIBILITY

Inclusion:

* ECOG Performance Score(PS) less than 2.
* Must be at least 18 years of age and capable of giving informed consent.
* Must be less than three years from the original diagnosis of Philadelphia chromosome positive CML in chronic phase.
* Patient is not in cytogenetic remission.
* No anticipation of bone marrow or stem cell transplant for six months unless these therapies are deemed necessary by a treatment physician due to the evolution of the disease;
* Concurrent treatment with hydroxyurea or Gleevec is allowed.PAST treatment with IFN alpha, Ara-C or other cytoxic agents is allowed
* Must not have any serious illness such that their medical condition might be compromised by participation in the study.
* Must have adequate renal function (serum creatinine \< 2.0), hepatic function (bilirubin and transaminase less than 2.0 x of the upper normal limit).
* Must not be on corticosteroid therapy, or other immunosuppressive medications.

Exclusion

* Patients with an ECOG Performance Score greater than or equal to 2.
* Patient is greater than or equal to 3 years out from the original diagnosis.
* Significant anemia (Hemoglobin \< 10 g/dl) and thrombocytopenia (platelet \< 20,000/ml) requiring transfusion.
* Peripheral blast count is over 10%.
* Positive urine or blood pregnancy test.
* Impaired renal function (serum creatinine \> 2.0), hepatic function (bilirubin and transaminase more than 2.0 x of the upper normal limit).
* Patient with significant active infection requiring hospitalization at the time of enrollment.
* Patient with significant behavioral or psychological problems that prevent adequate follow-up.
* Concurrent treatment with IFN alpha Ara-C or other cytotoxic agents (Gleevec and hydroxyurea are allowed.